the aid library

LIST OPTIONS

Filter

3612

Sort by:

Direction:

Download (239)

View PDF (211)

A checklist for respiratory pathogen pandemic preparedness planning

World Health Organization WHO (2023) C_WHO

This checklist is an operational tool to help national authorities develop or revise national respiratory pathogen (inclusive of influenza and coronaviruses) pandemic preparedness plans.

Download (232)

View PDF (415)

WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions

World Health Organization (2019) C_WHO

It is estimated that more than 311 000 women die of cervical cancer each year. Of these deaths, 91% occur in low- and middle-income countries. Demographic changes and a lack of action mean that the number of deaths per year is projected to reach 460 000 by 2040.

Download (273)

View PDF (368)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (231)

View PDF (181)

Global Accelerated Action for the Health of Adolescents (AA-HA!): guidance to support country implementation, second edition.

World Health Organization WHO (2023) C_WHO

The World Health Organization (WHO) is releasing the second edition of its Global Accelerated Action for the Health of Adolescents (AA-HA!) guidance. The document aims to equip governments to respond to the health and well-being challenges, opportunities and needs of adolescents. The guidance pro... more

Download (154)

View PDF (162)

Mental health, human rights and legislation: Guidance and practice

UN Office of the High Commissioner for Human Rights OHCHR, World Health Organization WHO (2023) C_WHO

WHO-OHCHR launch new guidance to improve laws addressing human rights abuses in mental health care Ahead of World Mental Health Day, the World Health Organization (WHO) and the Office of the High Commissioner on Human Rights (OHCHR) are jointly launching a new guidance, entitled "Mental health, h... more

Download (134)

View PDF (132)

WHO Guide to conducting programme reviews for HIV, viral hepatitis and sexually transmitted infections

World Health Organization WHO (2023) C_WHO

Sound periodic programme reviews provide opportunities for countries to objectively assess progress and take corrective action to sustain or get back on track towards achieving their medium and long-term programme goals. It reflects people’s diverse needs, enables efficient use of health system re... more

Download (156)

View PDF (142)

Guidance for country validation of viral hepatitis elimination and path to elimination

World Health Organization WHO (2023) C_WHO

Building on the 2021 Interim guidance, this second version and update, incorporates the lessons and feedback from the hepatitis pilots that successfully demonstrated the feasibility of measuring hepatitis B and C impact targets to demonstrate elimination, whilst highlighting challenges caused by hig... more

Download (127)

View PDF (138)

Towards UHC: thinking public

World Health Organisation (WHO) (2017) C_WHO

Past quantitative research on health financing has focused mostly on the level and distribution of total expenditure, with little emphasis on the specific role of public funds, despite their known importance for universal health coverage (UHC). Health Accounts data do not disaggregate public expendi... more

Download (136)

View PDF (136)

Public Spending on Health: A Closer Look at Global Trends

World Health Organisation (WHO) (2018) C_WHO

The 2018 global health financing report presents health spending data for all WHO Member States between 2000 and 2016 based on the SHA 2011 methodology. It shows a transformation trajectory for the global spending on health, with increasing domestic public funding and declining external financing. T... more

Download (156)

View PDF (133)

Communicating about Vaccination-related Risks

World Health Organisation (WHO) (2023) C_WHO

This document seeks to help health communication professionals working on the topic of immunization more effectively communicate about Events Supposedly Attributed to Vaccination and Immunization (ESAVI) by building trust in National Immunization Programs, understanding risk perceptions related to v... more

Download (207)

View PDF (219)

Global report on hypertension: the race against a silent killer
recommended

World Health Organisation (WHO) (2023) C_WHO

This report compiles data for the first time on the far-reaching consequences of uncontrolled hypertension, including heart attacks, strokes and premature death, along with substantial economic losses for communities and countries. It also contains information on the global, regional and country-lev... more

Download (156)

View PDF (207)

Malaria action plan for the Eastern Mediterranean Region, 2022-2030

World Health Organisation (WHO) (2023) C_WHO

This action plan is intended for senior-level decision-makers in ministries of health, malaria programme managers, entomologists, and epidemiologists working on malaria and other vectorborne diseases programmes. It is also intended for decision-makers and technical and advocacy staff at other orga... more

Download (163)

View PDF (162)

Voluntary non-remunerated blood donations to ensure blood safety in the WHO South-East Asia Region to support universal health coverage

World Health Organisation (WHO) (2023) C_WHO

Access to safe blood and blood products is recognized as one of the key requirements for delivery of modern health care in the journey towards health for all. The foundation of safe and sustainable blood supplies depends on the collection of blood from voluntary non-remunerated and low-risk donors. ... more

Download (187)

View PDF (188)

Global mapping report on multisectoral actions to strengthen the prevention and control of noncommunicable diseases and mental health conditions: experiences from around the world

World Health Organisation (WHO) (2023) C_WHO

There is growing understanding and high-level endorsement of the importance of strong collaborative multisectoral approaches to address a broad range of social, economic and governance issues for the prevention and control of noncommunicable disease (NCDs) and mental health conditions. In 2019, Worl... more

Download (215)

View PDF (211)

Guidance to facilitate monitoring and evaluation for antimicrobial resistance national action plans

Quadripartite: Food and Agriculture Organization of the United Nations FAO; UN Environment Programme UNEP; World Health Organization WHO; World Organisation for Animal Health WAHO (2023) CC

Antimicrobial resistance (AMR) is a global human, animal, plant and environment health threat that needs to be addressed by every country. The impacts of AMR are wide-ranging in terms of human health, animal health, food security and safety, environmental effects on ecosystems and biodiversity, and ...socioeconomic development. Just like the climate crisis, AMR poses a significant threat to the delivery of the 2030 Agenda for Sustainable Development. The response to the AMR crisis has been spearheaded through the global action plan on antimicrobial resistance (GAP-AMR), developed by the World Health Organization (WHO) in 2015, in close collaboration with the Food and Agriculture Organization of the United Nations (FAO) and the World Organisation for Animal Health (WOAH), and formally endorsed by the three organizations’ governing bodies and by the Political Declaration of the high-level meeting of the United Nations General Assembly on AMR in 2016. In 2022, the three organizations officially became the Quadripartite by welcoming the United Nations Environment Programme (UNEP) into the alliance “to accelerate coordination strategy on human, animal and ecosystem health”. The aim of the GAP-AMR is to ensure the continuity of successful treatment with effective and safe medicines. Its strategic objectives include: • improving the awareness and understanding of AMR; • strengthening the knowledge and evidence base through surveillance and research; • reducing the incidence of infection through effective sanitation, hygiene and infection prevention measures; optimizing the use of antimicrobial medicines in human and animal health; and • developing the economic case for sustainable investment that takes account of the needs of all countries and increasing investment in new medicines, diagnostic tools, vaccines and other interventions. With the adoption of the GAP-AMR, countries agreed to develop national action plans (NAPs) aligned with the GAP-AMR to mainstream AMR interventions nationally. Individually, the Quadripartite took action to advance AMR interventions in their respective sectors. FAO adopted a resolution on AMR recognizing that it poses an increasingly serious threat to public health and sustainable food production, and developed an AMR action plan to support the resolution’s implementation. For its part, WOAH developed a strategy on AMR aligned with the GAP-AMR, acknowledging the importance of a One Health approach to AMR. Similarly, more recently, UNEP’s governing body, the United Nations Environment Assembly, recognized that AMR is a current and increasing threat and a challenge to global health, food security and the sustainable development of all countries, and welcomed the GAP-AMR and the NAPs developed in accordance with its five overarching strategic objectives more

Download (189)

View PDF (172)

Clinical Management of Yellow Fever in the Region of the Americas. Experiences and Recommendations for Health Services

Pan American Health Organisation PAHO (2023) CC

The waves of yellow fever transmission in the Region of the Americas in 2016–2018 involved the largest number of human and epizootic cases to be reported in several decades. Yellow fever is a serious viral hemorrhagic disease that poses a challenge for health professionals. It requires early recog... more

Download (229)

View PDF (177)

Considerations for developing a national genomic surveillance strategy or action plan for pathogens with pandemic and epidemic potential

World Health Organization WHO (2023) C_WHO

Pathogen genomic surveillance has become a priority for public health systems in recent years. Genomic sequencing is increasingly being used to characterize pathogens and monitor important public health priorities (e.g. poliovirus, influenza virus, Mycobacterium tuberculosis and Vibrio cholerae, ant... more

Download (180)

View PDF (182)

Global Strategic preparedness, readiness and response plan for Cholera
recommended

World Health Organisation (WHO) (2023) CC

Cholera is a major health risk in many parts of the world, affecting millions of people every year. Since mid-2021, the world has been facing an acute upsurge of the 7th cholera pandemic, which is characterized by the number, size and concurrence of multiple outbreaks, the spread to areas that had b... more

Download (123)

View PDF (150)

A Compendium of Tools and Methods to Address Social Inequities Affecting the Health and Well-being of Women, Children, and Adolescents in Latin America and the Caribbean

Pan American Health Organization (PAHO) (2023) C_WHO

To support the achievement of health equity in the Region, the regional inter-agency movement Every Woman Every Child Latin America and the Caribbean (EWEC-LAC) advocates for and supports the use of equity and evidence-based policies, strategies and interventions to accelerate equitable progress in ... more

Download (137)

View PDF (159)

Mental health action plan for the WHO South-East Asia Region 2023–2030
recommended

World Health Organisation (WHO) (2023) C_WHO

Member States of the Region have initiated processes to strengthen leadership and governance for mental health. Several countries have developed and implemented mental health plans, strategies and legislations. Direct spending on mental health needs to be increased throughout the Region through the ... more

Global report on hypertension: the race against a silent killer recommended

Global Strategic preparedness, readiness and response plan for Cholera recommended

Mental health action plan for the WHO South-East Asia Region 2023–2030 recommended

Global report on hypertension: the race against a silent killer
recommended

Global Strategic preparedness, readiness and response plan for Cholera
recommended

Mental health action plan for the WHO South-East Asia Region 2023–2030
recommended